G. Amador | University of Nantes (original) (raw)

Papers by G. Amador

Douleurs : Evaluation - Diagnostic - Traitement, 2006

Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral,... more Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), and VAN-resistant EF, as well as common gram-negative pathogens. CPT is currently in phase 3 development. The objective of this study was to evaluate and compare the in vivo activity of CPT with LZO and VAN against EF strains using simulated human dosing in a REM. Methods: MICs for EF 12704 and EF NJ1 were 2 and 1 mg/L for CPT, 2 and >256 mg/L for VAN, and 2 and 1 mg/L for linezolid, respectively. The pharmacokinetics of CPT and comparators were determined to facilitate human dose simulation. Animals infected with one of the two EF strains were randomly assigned to no treatment (controls), CPT (computer-controlled infusion syringe pump simulating a human-equivalent (HE) dosage...

Endocarditis, 2012

Animal models of endocarditis are used extensively to test the in vivo activities of new drugs or... more Animal models of endocarditis are used extensively to test the in vivo activities of new drugs or new regimens, and are particularly suitable for PK and PD analysis and optimization of therapeutic efficacy. Experimental endocarditis studies played a major role in the exploration and assessment of new antistaphylococcal drugs beginning with the oxazolidinone, linezolid, in the early 2000s, and were critical to the recent approval of the promising anti-MRSA cephalosporin ceftaroline by the United States Food and Drug Administration (FDA). The endocarditis model is referenced in approximately 100 PubMed publications, most of which are assessments of the in vivo activity of new therapeutic options against Staphylococcus aureus such as linezolid (

Journal of Controlled Release, 2012

Since the beginning of the 1970s, controlled release technology has witnessed great advancement, ... more Since the beginning of the 1970s, controlled release technology has witnessed great advancement, and motivated numerous researchers in materials science. These systems overcome the drawbacks of traditional drug dosage form, and offer more effective and favorable methods to optimize drug delivery in optimum dose to specific sites or to prolong delivery duration. This paper deals with the synthesis of pH-controlled drug delivery systems for bone implant, allowing the local release of gentamicin sulfate (GS), an antibiotic commonly used to prevent infections during orthopedic surgeries. We present a biomaterial synthesis allowing the controlled release of GS at the site of surgical implantation (over an adjustable period of time). In our design, spherical nanoparticles (NPs) functionalized by the chosen antibiotic (Gentamicin sulfate, GS), are chemically anchored to the biomaterial surface. A cleavage reaction of the chemical bond between NPs and GS, effected by the contact of material with a solution presenting an acidic pH (in the case of infection, there is a decrease of the physiological medium pH), induces controlled release of the bioactive molecule in its native form. In this paper, we discuss the synthesis of a bioactive titanium based biomaterial in general, and the grafting of the NPs onto the titanium surfaces in particular. We have paid particular attention to the characterization of the drug surface density and the release kinetic of the active molecule as a function of the pH. In vitro bacterial growth inhibition tests after GS delivery at acidic pH (with Staphylococcus aureus) have also been carried out in order to prove the efficiency of such biomaterials.

Journal of Antimicrobial Chemotherapy, 2010

To evaluate the activity of a new cephalosporin, ceftaroline, in comparison with other antistaphy... more To evaluate the activity of a new cephalosporin, ceftaroline, in comparison with other antistaphylococcal drugs (linezolid and vancomycin) at projected human therapeutic doses against methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains. Methods: Using a rabbit experimental model of acute osteomyelitis, efficacy was assessed following 4 days of treatment by colony counts of infected bone tissues (joint fluid, femoral bone marrow and bone). Results: Although vancomycin remains the standard treatment for MRSA osteomyelitis, it was ineffective against the MRSA strain and poorly active against GISA infections in this model. Ceftaroline and linezolid demonstrated significant activity in bone marrow and bone, and were significantly better than vancomycin treatment. However, ceftaroline was the only drug to exhibit significant activity against MRSA in infected joint fluid. Conclusions: The present study supports ceftaroline as a promising therapeutic option for the treatment of severe MRSA infections, including osteomyelitis.

Journal of Antimicrobial Chemotherapy, 2010

Journal of Antimicrobial Chemotherapy, 2012

Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison ... more Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison with ceftazidime and piperacillin/tazobactam against a multidrug-resistant Pseudomonas aeruginosa strain using a murine model of pneumonia. Methods: Quantitative bacteriology, survival, histological examination, myeloperoxidase activity, proinflammatory cytokine levels in lungs and endothelial permeability were evaluated to determine the effects of ceftolozane and comparators on P. aeruginosa-induced pneumonia. Results: After 48 h of treatment, ceftolozane reduced the bacterial load by 3-4 log 10 cfu/g of lung. Systemic dissemination of the pulmonary infection and development of lung damage were inhibited in all b-lactamtreated animals. P. aeruginosa-induced pneumonia led to elevated concentrations of tumour necrosis factora, interleukin (IL)-1b and macrophage inflammatory protein (MIP)-2 in the lungs. While the levels of proinflammatory cytokines decreased following ceftazidime and piperacillin/tazobactam therapy, ceftolozane exhibited increased concentrations of IL-1b and MIP-2 after 24 h of infection, resulted in significantly increased levels of recruited neutrophils within the infected lung without increasing lung endothelial permeability. Conclusions: These data strongly support ceftolozane as an effective option for the treatment of severe P. aeruginosa respiratory infections by improving the early pulmonary inflammatory response without impairing 48 h post-infection homeostasis.

International Journal of Antimicrobial Agents, 2010

Antimicrobial Agents and Chemotherapy, 2009

The antimicrobial activities of calcium-deficient apatite loaded with different concentrations (2... more The antimicrobial activities of calcium-deficient apatite loaded with different concentrations (25, 100, and 500 μg/mg) of vancomycin as a filling biomaterial were evaluated in a methicillin-resistant Staphylococcus aureus (MRSA) rabbit acute osteomyelitis model. Bacterial counts in bone, bone marrow, and joint fluid samples treated with forms of the apatite were compared to those in tissue samples receiving a constant intravenous vancomycin infusion after 4 days. This study demonstrates that using a calcium-deficient apatite loaded with vancomycin dramatically decreases the bacterial counts in bone and marrow.

Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic a... more Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic agents like antibiotics to form drug-delivery systems. Vancomycin (V), considered as the standard treatment for osteomyelitis, is criticized for its poor penetration in bone tissues. The aim of this work was to assess the in vivo contribution of vancomycin introduced by wet granulation onto CDA microparticles for 2.5, 10 and 50 percent per gram. Methods: Femoral trepanation of rabbits was performed, followed by injection of 109 CFU MRSA (vancomycin MIC 1µg/mL) suspension into the knee cavity. A surgical debridment of the infected tissues was performed 3 days later and animals were randomly assigned to: V (vancomycin constant IV infusion to reach a 20xMIC serum steady-state concentration as a control group), V+CDA V2.5% or V10% (100 mg CDA with vancomycin 25 or 100 µg/mg filling in addition to constant IV infusion) and CDA V2.5%, V10% and V50% (100 mg CDA with vancomycin 25, 100 and 500 µg...

Purpose: The activity of a new broad-spectrum cephalosporin, CPT, was compared with that of other... more Purpose: The activity of a new broad-spectrum cephalosporin, CPT, was compared with that of other antistaphylococcal drugs in a rabbit OEM. Methods: Femoral trepanation of rabbits was performed, followed by injection of 109 CFU S aureus suspension into the knee cavity. A surgical debridment of the infected tissues was performed 3 days later and animals were randomly assigned to: no treatment (controls), CPT (simulating a human-equivalent (HE) dose of 10 mg/kg/12h), LZO (HE dose of 10 mg/kg/12h), and VAN (constant IV infusion to reach a 20xMIC serum steady-state concentration). Surviving bacteria were counted in joint fluid (JF), bone marrow (BM) and bone (BQ) at day 3 and at the end of 4-days treatment (day 7). Results: Mean ± SD Δlog10 CFU/g of Tissue (day 7 - day 3) Treatment MRSA GISA JF BM BO JF BM BO Controls 0.10±0.69 0.19±0.68 0.10±0.87 0.83±0.35 0.64±0.72 0.22±0.55 CPT -1.98±1.0bde -2.95±0.44ac -2.83±1.50ac -1.55±0.52a -2.02±0.93ac -2.01±0.90ac LZO -0.77±1.39 -2.69±1.92bd -2...

Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral,... more Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), and VAN-resistant EF, as well as common gram-negative pathogens. CPT is currently in phase 3 development. The objective of this study was to evaluate and compare the in vivo activity of CPT with LZO and VAN against EF strains using simulated human dosing in a REM. Methods: MICs for EF 12704 and EF NJ1 were 2 and 1 mg/L for CPT, 2 and >256 mg/L for VAN, and 2 and 1 mg/L for linezolid, respectively. The pharmacokinetics of CPT and comparators were determined to facilitate human dose simulation. Animals infected with one of the two EF strains were randomly assigned to no treatment (controls), CPT (computer-controlled infusion syringe pump simulating a human-equivalent (HE) dosage...

Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic a... more Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic agents like antibiotics to form drug-delivery systems. Vancomycin (V), considered as the standard treatment for osteomyelitis, is criticized for its poor penetration in bone tissues. The aim of this work was to assess the in vivo contribution of vancomycin introduced by wet granulation onto CDA microparticles for 2.5, 10 and 50 percent per gram. Methods: Femoral trepanation of rabbits was performed, followed by injection of 109 CFU MRSA (vancomycin MIC 1µg/mL) suspension into the knee cavity. A surgical debridment of the infected tissues was performed 3 days later and animals were randomly assigned to: V (vancomycin constant IV infusion to reach a 20xMIC serum steady-state concentration as a control group), V+CDA V2.5% or V10% (100 mg CDA with vancomycin 25 or 100 µg/mg filling in addition to constant IV infusion) and CDA V2.5%, V10% and V50% (100 mg CDA with vancomycin 25, 100 and 500 µg...

Background: CXA-101 (CXA) is a novel parenteral cephalosporin with potent in vitro activity again... more Background: CXA-101 (CXA) is a novel parenteral cephalosporin with potent in vitro activity against Klebsiella pneumoniae (KP), and, in combination with tazobactam (TAZ), against extended-spectrum β-lactamase (ESBL) producers. The aim of this study was to determine the dose that is pharmacologically effective for 50% of the population exposed (ED50) of the new cephalosporin, CXA, alone or in combination with the β-lactamase inhibitor TAZ (in a fixed 2:1 ratio), in comparison with ceftazidime (CAZ) and piperacillin-tazobactam (TZP) against ESBL-producing KPs.

Journal of Antimicrobial Chemotherapy, 2013

Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison ... more Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison with ceftazidime and piperacillin/tazobactam against a multidrug-resistant Pseudomonas aeruginosa strain using a murine model of pneumonia.

Journal of Antimicrobial Chemotherapy

Keywords: MRSA, animal model, outpatient antibiotic therapy Sir, Ceftaroline fosamil is the prodr... more Keywords: MRSA, animal model, outpatient antibiotic therapy Sir, Ceftaroline fosamil is the prodrug form of a novel, parenteral, broad-spectrum cephalosporin, ceftaroline, exhibiting bactericidal activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), as well as common Gram-negative pathogens. 1 To date, Phase III trials using intravenous (iv) administration of ceftaroline fosamil (herein after referred to as ceftaroline) have been completed for complicated skin and skin structure infections and for community-associated pneumonia.

Douleurs : Evaluation - Diagnostic - Traitement, 2006

Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral,... more Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), and VAN-resistant EF, as well as common gram-negative pathogens. CPT is currently in phase 3 development. The objective of this study was to evaluate and compare the in vivo activity of CPT with LZO and VAN against EF strains using simulated human dosing in a REM. Methods: MICs for EF 12704 and EF NJ1 were 2 and 1 mg/L for CPT, 2 and >256 mg/L for VAN, and 2 and 1 mg/L for linezolid, respectively. The pharmacokinetics of CPT and comparators were determined to facilitate human dose simulation. Animals infected with one of the two EF strains were randomly assigned to no treatment (controls), CPT (computer-controlled infusion syringe pump simulating a human-equivalent (HE) dosage...

Endocarditis, 2012

Animal models of endocarditis are used extensively to test the in vivo activities of new drugs or... more Animal models of endocarditis are used extensively to test the in vivo activities of new drugs or new regimens, and are particularly suitable for PK and PD analysis and optimization of therapeutic efficacy. Experimental endocarditis studies played a major role in the exploration and assessment of new antistaphylococcal drugs beginning with the oxazolidinone, linezolid, in the early 2000s, and were critical to the recent approval of the promising anti-MRSA cephalosporin ceftaroline by the United States Food and Drug Administration (FDA). The endocarditis model is referenced in approximately 100 PubMed publications, most of which are assessments of the in vivo activity of new therapeutic options against Staphylococcus aureus such as linezolid (

Journal of Controlled Release, 2012

Since the beginning of the 1970s, controlled release technology has witnessed great advancement, ... more Since the beginning of the 1970s, controlled release technology has witnessed great advancement, and motivated numerous researchers in materials science. These systems overcome the drawbacks of traditional drug dosage form, and offer more effective and favorable methods to optimize drug delivery in optimum dose to specific sites or to prolong delivery duration. This paper deals with the synthesis of pH-controlled drug delivery systems for bone implant, allowing the local release of gentamicin sulfate (GS), an antibiotic commonly used to prevent infections during orthopedic surgeries. We present a biomaterial synthesis allowing the controlled release of GS at the site of surgical implantation (over an adjustable period of time). In our design, spherical nanoparticles (NPs) functionalized by the chosen antibiotic (Gentamicin sulfate, GS), are chemically anchored to the biomaterial surface. A cleavage reaction of the chemical bond between NPs and GS, effected by the contact of material with a solution presenting an acidic pH (in the case of infection, there is a decrease of the physiological medium pH), induces controlled release of the bioactive molecule in its native form. In this paper, we discuss the synthesis of a bioactive titanium based biomaterial in general, and the grafting of the NPs onto the titanium surfaces in particular. We have paid particular attention to the characterization of the drug surface density and the release kinetic of the active molecule as a function of the pH. In vitro bacterial growth inhibition tests after GS delivery at acidic pH (with Staphylococcus aureus) have also been carried out in order to prove the efficiency of such biomaterials.

Journal of Antimicrobial Chemotherapy, 2010

To evaluate the activity of a new cephalosporin, ceftaroline, in comparison with other antistaphy... more To evaluate the activity of a new cephalosporin, ceftaroline, in comparison with other antistaphylococcal drugs (linezolid and vancomycin) at projected human therapeutic doses against methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains. Methods: Using a rabbit experimental model of acute osteomyelitis, efficacy was assessed following 4 days of treatment by colony counts of infected bone tissues (joint fluid, femoral bone marrow and bone). Results: Although vancomycin remains the standard treatment for MRSA osteomyelitis, it was ineffective against the MRSA strain and poorly active against GISA infections in this model. Ceftaroline and linezolid demonstrated significant activity in bone marrow and bone, and were significantly better than vancomycin treatment. However, ceftaroline was the only drug to exhibit significant activity against MRSA in infected joint fluid. Conclusions: The present study supports ceftaroline as a promising therapeutic option for the treatment of severe MRSA infections, including osteomyelitis.

Journal of Antimicrobial Chemotherapy, 2010

Journal of Antimicrobial Chemotherapy, 2012

Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison ... more Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison with ceftazidime and piperacillin/tazobactam against a multidrug-resistant Pseudomonas aeruginosa strain using a murine model of pneumonia. Methods: Quantitative bacteriology, survival, histological examination, myeloperoxidase activity, proinflammatory cytokine levels in lungs and endothelial permeability were evaluated to determine the effects of ceftolozane and comparators on P. aeruginosa-induced pneumonia. Results: After 48 h of treatment, ceftolozane reduced the bacterial load by 3-4 log 10 cfu/g of lung. Systemic dissemination of the pulmonary infection and development of lung damage were inhibited in all b-lactamtreated animals. P. aeruginosa-induced pneumonia led to elevated concentrations of tumour necrosis factora, interleukin (IL)-1b and macrophage inflammatory protein (MIP)-2 in the lungs. While the levels of proinflammatory cytokines decreased following ceftazidime and piperacillin/tazobactam therapy, ceftolozane exhibited increased concentrations of IL-1b and MIP-2 after 24 h of infection, resulted in significantly increased levels of recruited neutrophils within the infected lung without increasing lung endothelial permeability. Conclusions: These data strongly support ceftolozane as an effective option for the treatment of severe P. aeruginosa respiratory infections by improving the early pulmonary inflammatory response without impairing 48 h post-infection homeostasis.

International Journal of Antimicrobial Agents, 2010

Antimicrobial Agents and Chemotherapy, 2009

The antimicrobial activities of calcium-deficient apatite loaded with different concentrations (2... more The antimicrobial activities of calcium-deficient apatite loaded with different concentrations (25, 100, and 500 μg/mg) of vancomycin as a filling biomaterial were evaluated in a methicillin-resistant Staphylococcus aureus (MRSA) rabbit acute osteomyelitis model. Bacterial counts in bone, bone marrow, and joint fluid samples treated with forms of the apatite were compared to those in tissue samples receiving a constant intravenous vancomycin infusion after 4 days. This study demonstrates that using a calcium-deficient apatite loaded with vancomycin dramatically decreases the bacterial counts in bone and marrow.

Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic a... more Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic agents like antibiotics to form drug-delivery systems. Vancomycin (V), considered as the standard treatment for osteomyelitis, is criticized for its poor penetration in bone tissues. The aim of this work was to assess the in vivo contribution of vancomycin introduced by wet granulation onto CDA microparticles for 2.5, 10 and 50 percent per gram. Methods: Femoral trepanation of rabbits was performed, followed by injection of 109 CFU MRSA (vancomycin MIC 1µg/mL) suspension into the knee cavity. A surgical debridment of the infected tissues was performed 3 days later and animals were randomly assigned to: V (vancomycin constant IV infusion to reach a 20xMIC serum steady-state concentration as a control group), V+CDA V2.5% or V10% (100 mg CDA with vancomycin 25 or 100 µg/mg filling in addition to constant IV infusion) and CDA V2.5%, V10% and V50% (100 mg CDA with vancomycin 25, 100 and 500 µg...

Purpose: The activity of a new broad-spectrum cephalosporin, CPT, was compared with that of other... more Purpose: The activity of a new broad-spectrum cephalosporin, CPT, was compared with that of other antistaphylococcal drugs in a rabbit OEM. Methods: Femoral trepanation of rabbits was performed, followed by injection of 109 CFU S aureus suspension into the knee cavity. A surgical debridment of the infected tissues was performed 3 days later and animals were randomly assigned to: no treatment (controls), CPT (simulating a human-equivalent (HE) dose of 10 mg/kg/12h), LZO (HE dose of 10 mg/kg/12h), and VAN (constant IV infusion to reach a 20xMIC serum steady-state concentration). Surviving bacteria were counted in joint fluid (JF), bone marrow (BM) and bone (BQ) at day 3 and at the end of 4-days treatment (day 7). Results: Mean ± SD Δlog10 CFU/g of Tissue (day 7 - day 3) Treatment MRSA GISA JF BM BO JF BM BO Controls 0.10±0.69 0.19±0.68 0.10±0.87 0.83±0.35 0.64±0.72 0.22±0.55 CPT -1.98±1.0bde -2.95±0.44ac -2.83±1.50ac -1.55±0.52a -2.02±0.93ac -2.01±0.90ac LZO -0.77±1.39 -2.69±1.92bd -2...

Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral,... more Background: Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), and VAN-resistant EF, as well as common gram-negative pathogens. CPT is currently in phase 3 development. The objective of this study was to evaluate and compare the in vivo activity of CPT with LZO and VAN against EF strains using simulated human dosing in a REM. Methods: MICs for EF 12704 and EF NJ1 were 2 and 1 mg/L for CPT, 2 and >256 mg/L for VAN, and 2 and 1 mg/L for linezolid, respectively. The pharmacokinetics of CPT and comparators were determined to facilitate human dose simulation. Animals infected with one of the two EF strains were randomly assigned to no treatment (controls), CPT (computer-controlled infusion syringe pump simulating a human-equivalent (HE) dosage...

Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic a... more Background: Nanocrystalline calcium-deficient apatites (CDA) can be associated with therapeutic agents like antibiotics to form drug-delivery systems. Vancomycin (V), considered as the standard treatment for osteomyelitis, is criticized for its poor penetration in bone tissues. The aim of this work was to assess the in vivo contribution of vancomycin introduced by wet granulation onto CDA microparticles for 2.5, 10 and 50 percent per gram. Methods: Femoral trepanation of rabbits was performed, followed by injection of 109 CFU MRSA (vancomycin MIC 1µg/mL) suspension into the knee cavity. A surgical debridment of the infected tissues was performed 3 days later and animals were randomly assigned to: V (vancomycin constant IV infusion to reach a 20xMIC serum steady-state concentration as a control group), V+CDA V2.5% or V10% (100 mg CDA with vancomycin 25 or 100 µg/mg filling in addition to constant IV infusion) and CDA V2.5%, V10% and V50% (100 mg CDA with vancomycin 25, 100 and 500 µg...

Background: CXA-101 (CXA) is a novel parenteral cephalosporin with potent in vitro activity again... more Background: CXA-101 (CXA) is a novel parenteral cephalosporin with potent in vitro activity against Klebsiella pneumoniae (KP), and, in combination with tazobactam (TAZ), against extended-spectrum β-lactamase (ESBL) producers. The aim of this study was to determine the dose that is pharmacologically effective for 50% of the population exposed (ED50) of the new cephalosporin, CXA, alone or in combination with the β-lactamase inhibitor TAZ (in a fixed 2:1 ratio), in comparison with ceftazidime (CAZ) and piperacillin-tazobactam (TZP) against ESBL-producing KPs.

Journal of Antimicrobial Chemotherapy, 2013

Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison ... more Objectives: To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison with ceftazidime and piperacillin/tazobactam against a multidrug-resistant Pseudomonas aeruginosa strain using a murine model of pneumonia.

Journal of Antimicrobial Chemotherapy

Keywords: MRSA, animal model, outpatient antibiotic therapy Sir, Ceftaroline fosamil is the prodr... more Keywords: MRSA, animal model, outpatient antibiotic therapy Sir, Ceftaroline fosamil is the prodrug form of a novel, parenteral, broad-spectrum cephalosporin, ceftaroline, exhibiting bactericidal activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), as well as common Gram-negative pathogens. 1 To date, Phase III trials using intravenous (iv) administration of ceftaroline fosamil (herein after referred to as ceftaroline) have been completed for complicated skin and skin structure infections and for community-associated pneumonia.